These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36064123)

  • 1. Design, synthesis and biological evaluation of novel macrocyclic derivatives bearing aniline pyrimidine scaffolds as EGFR-TKIs.
    Shen Y; Xiao X; Zhang P; Wang Q; Zhu X; Yang Y; Chen Y
    Bioorg Med Chem Lett; 2022 Nov; 75():128970. PubMed ID: 36064123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of novel osimertinib derivatives as reversible EGFR kinase inhibitors.
    Ding S; Gao Z; Hu Z; Qi R; Zheng X; Dong X; Zhang M; Shen J; Long T; Zhu Y; Tian L; Song W; Liu R; Li Y; Sun J; Duan W; Liu J; Chen Y
    Eur J Med Chem; 2022 Aug; 238():114492. PubMed ID: 35696862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural modifications on indole and pyrimidine rings of osimertinib lead to high selectivity towards L858R/T790M double mutant enzyme and potent antitumor activity.
    Liu Q; Luo Y; Li Z; Chen C; Fang L
    Bioorg Med Chem; 2021 Apr; 36():116094. PubMed ID: 33667898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, and Biological Evaluation of Dual Inhibitors of EGFR
    Wang A; Shuai W; Wu C; Pei J; Yang P; Wang X; Li S; Liu J; Wang Y; Wang G; Ouyang L
    J Med Chem; 2024 Feb; 67(4):2777-2801. PubMed ID: 38323982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of highly potent and selective EGFR
    Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
    Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation.
    Zhu Y; Ye X; Wu Y; Shen H; Cai Z; Xia F; Min W; Hou Y; Wang L; Wang X; Xiao Y; Yang P
    J Med Chem; 2024 May; 67(9):7283-7300. PubMed ID: 38676656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel aminopyrimidine derivatives for the treatment of mutant NSCLC.
    Hu L; Shi S; Song X; Ma F; Ji O; Qi B
    Eur J Med Chem; 2024 Feb; 265():116074. PubMed ID: 38142512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
    Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
    Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H
    Zheng YG; Zhang WQ; Meng L; Wu XQ; Zhang L; An L; Li CL; Gao CY; Xu L; Liu Y
    Eur J Med Chem; 2020 Sep; 202():112522. PubMed ID: 32619886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.
    Kashima K; Kawauchi H; Tanimura H; Tachibana Y; Chiba T; Torizawa T; Sakamoto H
    Mol Cancer Ther; 2020 Nov; 19(11):2288-2297. PubMed ID: 32943545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
    Cross DA; Ashton SE; Ghiorghiu S; Eberlein C; Nebhan CA; Spitzler PJ; Orme JP; Finlay MR; Ward RA; Mellor MJ; Hughes G; Rahi A; Jacobs VN; Red Brewer M; Ichihara E; Sun J; Jin H; Ballard P; Al-Kadhimi K; Rowlinson R; Klinowska T; Richmond GH; Cantarini M; Kim DW; Ranson MR; Pao W
    Cancer Discov; 2014 Sep; 4(9):1046-61. PubMed ID: 24893891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Pyrimidine-5-Carbonitriles as potential apoptotic and antiproliferative agents by dual inhibition of EGFR
    Reda N; Mohamed KO; Abdou K; Helwa AA; Elshewy A
    Bioorg Chem; 2024 Apr; 145():107185. PubMed ID: 38350273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and Evaluation of 2-Amine-4-oxyphosaniline Pyrimidine Derivatives as EGFR L858R/T790M/C797S Mutant Inhibitors.
    Zhang M; Yang Y; Wang Y; Wang J; Wu H; Zhu Y
    Chem Pharm Bull (Tokyo); 2023 Feb; 71(2):140-147. PubMed ID: 36517026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies.
    Zhai X; Ward RA; Doig P; Argyrou A
    Biochemistry; 2020 Apr; 59(14):1428-1441. PubMed ID: 32207968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hybrids of Quinoline and Anilinopyrimidine: Novel EGFRT790M Inhibitors with Antiproliferative Activity against Non-Small Cell Lung Cancer Cell Lines.
    Han C; Ren J; Su F; Hu X; Li M; Wang Z; Wu L
    Anticancer Agents Med Chem; 2020; 20(6):724-733. PubMed ID: 32116203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
    Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K
    Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
    Li J; An B; Song X; Zhang Q; Chen C; Wei S; Fan R; Li X; Zou Y
    Eur J Med Chem; 2021 Feb; 212():113019. PubMed ID: 33429247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib.
    Obst-Sander U; Ricci A; Kuhn B; Friess T; Koldewey P; Kuglstatter A; Hewings D; Goergler A; Steiner S; Rueher D; Imhoff MP; Raschetti N; Marty HP; Dietzig A; Rynn C; Ehler A; Burger D; Kornacker M; Schaffland JP; Herting F; Pao W; Bischoff JR; Martoglio B; Alice Nagel Y; Jaeschke G
    J Med Chem; 2022 Oct; 65(19):13052-13073. PubMed ID: 36178776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations.
    Xia Z; Huang R; Zhou X; Chai Y; Chen H; Ma L; Yu Q; Li Y; Li W; He Y
    Eur J Med Chem; 2021 Nov; 224():113711. PubMed ID: 34315040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.